PDCD1 and cancer: Routy et al. then confirmed the negative influence of ABT exposure on the GM-ICI axis through their work with ABT-treated mice, demonstrating restoration of anti-PD-1 therapy responsiveness following FMT from PD-1 responsive cancer patients [15].